2023-04-26 06:05:15
Posted Apr 26, 2023, 8:05 AM
April 26 (Archyde.com) – Roche reported a 7% decline in first-quarter sales on Wednesday, driven by lower demand for its COVID-19-related products and diagnostic tests, but less of a decline. higher than that anticipated by analysts due to strong revenue growth from other pharmaceuticals.
The group’s quarterly turnover fell to 15.3 billion Swiss francs (15.64 billion euros), the pharmaceutical group said, beating market expectations of 14.8 billion francs.
Roche does not publish results for its first and third quarters.
Revenue and basic earnings per share are expected to decline between 1% and 5% in 2023, the Swiss group added. (Report Ludwig Burger, French version Augustin Turpin, edited by Blandine Hénault)
What stocks to buy?
Making the best investments requires in-depth knowledge of the markets, their mechanisms, of the economy and involves diving into the heart of the strategy of each of the listed companies. The editorial staff of Investir does it for you and provides its subscribers with advice on more than 800 securities. Benefit from their buy, speculative buy, spread or sell recommendations by subscribing to Investir.
I discover the offers
1682490409
#RocheQ1 #sales #fall #demand #falls #due #COVID19
